Advances Against Aspergillosis I

Regular price €90.99
Age Group_Uncategorized
Age Group_Uncategorized
agents
application
aspergillosis
automatic-update
B01=David S. Perlin
B01=Karl V. Clemons
B01=Malcolm D. Richardson
Category1=Non-Fiction
Category=PSAF
Category=PSG
children
clinical
contain
COP=United Kingdom
Delivery_Delivery within 10-20 working days
diagnostic
encapsulating
eq_isMigrated=2
eq_non-fiction
eq_science
findings
immunocompromised patients
invasive
Language_English
markers
PA=Available
Price_€50 to €100
PS=Active
risk
short
SN=Annals of the New York Academy of Sciences
softlaunch
stratification
topics
treatment
use

Product details

  • ISBN 9781573318549
  • Weight: 227g
  • Dimensions: 178 x 255mm
  • Publication Date: 22 Feb 2013
  • Publisher: John Wiley and Sons Ltd
  • Publication City/Country: GB
  • Product Form: Paperback
  • Language: English
Delivery/Collection within 10-20 working days

Our Delivery Time Frames Explained
2-4 Working Days: Available in-stock

10-20 Working Days
: On Backorder

Will Deliver When Available
: On Pre-Order or Reprinting

We ship your order once all items have arrived at our warehouse and are processed. Need those 2-4 day shipping items sooner? Just place a separate order for them!

Aspergillosis, the leading fungal cause of mortality in immunocompromised patients, presents a serious worldwide challenge—particularly in the face of increasing antifungal resistance.  Bringing together the world’s leaders in the Aspergillus and aspergillosis fields to promote cross-disciplinary collaboration among clinicians, industry, and scientific experts, the “Advances Against Aspergillosis” conference was held January 26–28, 2012 in Istanbul, Turkey. 

This first of two Annals volumes contains short reviews encapsulating recent clinical findings on aspergillosis.  Among the topics included are the application of diagnostic markers to invasive aspergillosis in children, risk stratification for invasive aspergillosis in immunocompromised patients, use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis,   immune regulation in idiopathic bronchiectasis, and management of chronic pulmonary aspergillosis.

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit: http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.111/(ISSN)1749-6632.

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information on becoming a member.

Karl V Clemons, Stanford University, Stanford, California.

Malcolm Richardson, University of Manchester, Manchester, United Kingdom.

David S Perlin, UMDNJ-New Jersey Medical School, Newark, New Jersey.